AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22452841 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic EMLA (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 25
Study 22452841 — intervention group
Group type: EXPERIMENTAL
Intervention: LMX-4 (4% lidocaine)
Number of subjects: 25
Study 22452841 — intervention group
Group type: EXPERIMENTAL
Intervention: BLT (20% benzoncaine, 6% lidocaine, and 4% tetracaine)
Number of subjects: 25
Study 22452841 — intervention group
Group type: EXPERIMENTAL
Intervention: LET (4% lidocaine, 1:2000 epinephrine, and 0.5% tetracaine)
Number of subjects: 25
Study 22452841 — intervention group
Group type: COMPARATOR
Intervention: OTC preparations (overall)
Number of subjects: 25
Study 22452841 — intervention group
Group type: COMPARATOR
Intervention: 4% lidocaine-containing preparations
Number of subjects: 25
Study 22452841 — intervention group
Group type: COMPARATOR
Intervention: Adverse reactions
Number of subjects: 25
Study 20405046 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterministic case definition of malaria caused fever (fever and parasite density above a certain cutoff)
Number of subjects: 0
Study 20405046 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic case definition of malaria caused fever (probability estimation of fever caused by malaria)
Number of subjects: 0
Study 17565490 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week triple therapy with rabeprazole 10 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 250 mg b.i.d. (RAM)
Number of subjects: 132
Study 17565490 — intervention group
Group type: COMPARATOR
Intervention: 2-week dual therapy with rabeprazole 10 mg q.i.d. and amoxicillin 500 mg q.i.d. (RA)
Number of subjects: 132
Study 16359953 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of cryodamaged blastomeres (in the study group) during frozen-thawed ET
Number of subjects: 88
Study 16359953 — intervention group
Group type: COMPARATOR
Intervention: Control group (no removal of lysed blastomeres) during frozen-thawed ET
Number of subjects: 88
Study 12111046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 24
Study 12111046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (DIET)
Number of subjects: 24
Study 12111046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy combined with Dietary Intervention (HRT+DIET)
Number of subjects: 24
Study 10621764 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency telephone support in addition to treatment as usual (intervention group)
Number of subjects: 827
Study 10621764 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 827
Study 8901820 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fractions from preeclamptic women
Number of subjects: 0
Study 8901820 — intervention group
Group type: COMPARATOR
Intervention: Plasma fractions from normal pregnant women
Number of subjects: 0
Study 1813429 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified double-flared technique
Number of subjects: 60
Study 1813429 — intervention group
Group type: COMPARATOR
Intervention: Double-flared technique
Number of subjects: 60
Study 6729651 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose weekly fractionation regimen
Number of subjects: 83
Study 6729651 — intervention group
Group type: COMPARATOR
Intervention: Conventional daily fractionation schedule
Number of subjects: 83
Study 30847689 — intervention group
Group type: EXPERIMENTAL
Intervention: Food exposure session in a partial hospital eating disorder center
Number of subjects: 42
Study 30195243 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect intervention (n=55)
Number of subjects: 110
Study 30195243 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition (n=55)
Number of subjects: 110
Study 27328808 — intervention group
Group type: EXPERIMENTAL
Intervention: CB12 (0.3% zinc acetate and 0.025% chlorhexidine)
Number of subjects: 34
Study 27328808 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 34
Study 24343275 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated sodium butyrate (MSB) 300 mg daily
Number of subjects: 73
Study 24343275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 22404668 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia as neuroprotection during surgery
Number of subjects: 1001
Study 19938151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hcy‐lowering therapy (5 mg folate and 1500 microg vitamin B(12) daily)
Number of subjects: 42
Study 19938151 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐lipoic acid (alpha‐LA) therapy (1200 mg daily)
Number of subjects: 42
Study 19938151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 19099975 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress group (ACS)
Number of subjects: 100
Study 19099975 — intervention group
Group type: COMPARATOR
Intervention: Non-psychological stress group (ACS)
Number of subjects: 100
Study 19099975 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS group
Number of subjects: 100
Study 19099975 — intervention group
Group type: COMPARATOR
Intervention: SA group
Number of subjects: 100
Study 16041896 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week cognitive-behavioral bereavement coping group intervention
Number of subjects: 235
Study 16041896 — intervention group
Group type: COMPARATOR
Intervention: Individual psychotherapy upon request
Number of subjects: 235
Study 12443969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% C31G hydroxyethyl cellulose (HEC)
Number of subjects: 60
Study 12443969 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nonoxynol‐9 (N‐9) (Gynol II)
Number of subjects: 60
Study 12443969 — intervention group
Group type: COMPARATOR
Intervention: HEC vehicle
Number of subjects: 60
Study 12443969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% C31G HEC
Number of subjects: 60
Study 12443969 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nonoxynol‐9 (N‐9)
Number of subjects: 60
Study 10434220 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol vapor
Number of subjects: 91
Study 10434220 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 91
Study 7872875 — intervention group
Group type: EXPERIMENTAL
Intervention: selegiline hydrochloride (10 mg/d)
Number of subjects: 800
Study 7872875 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 800
Study 2219469 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Mycobacterium vaccae (10^9 irradiation‐killed M. vaccae)
Number of subjects: 47
Study 2219469 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Mycobacterium vaccae
Number of subjects: 47
Study 2219469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 47
Study 660709 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tuberculosis drugs and oral iron
Number of subjects: 21
Study 660709 — intervention group
Group type: COMPARATOR
Intervention: Anti-tuberculosis drugs only
Number of subjects: 21
Study 31618176 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of concurrent aerobic (60‐80% heart rate reserve) and resistance (40‐65% of 1RM) training
Number of subjects: 20
Study 31618176 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 27748083 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 25 mg plus MTX
Number of subjects: 378
Study 27748083 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 50 mg plus MTX
Number of subjects: 378
Study 27748083 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg plus MTX
Number of subjects: 378
Study 27748083 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg plus MTX
Number of subjects: 378
Study 27748083 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 378
Study 26654721 — intervention group
Group type: EXPERIMENTAL
Intervention: Family meetings (FM)
Number of subjects: 0
Study 23482645 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV DNA vaccine (4 mg) coding for clade B Gag, Pol, and Nef and clade A, B, and C Env, followed by a replication-deficient adenovirus type 5 boost (10^10 particle units)
Number of subjects: 17
Study 23482645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21490144 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate administration
Number of subjects: 14
Study 21490144 — intervention group
Group type: COMPARATOR
Intervention: BCAA supplementation during phenylbutyrate therapy
Number of subjects: 14
Study 19551673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Combination (FC) therapy as second choice
Number of subjects: 50
Study 19551673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Combination (FC) therapy as third choice
Number of subjects: 50
Study 19551673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Combination (FC) therapy as first choice
Number of subjects: 50
Study 19551673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol FC
Number of subjects: 50
Study 19551673 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol FC
Number of subjects: 50
Study 19551673 — intervention group
Group type: EXPERIMENTAL
Intervention: FC therapy overall
Number of subjects: 50
Study 19551673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol FC
Number of subjects: 50
Study 19551673 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandins dosing time
Number of subjects: 50
Study 16710082 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day)
Number of subjects: 28
Study 16710082 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants (target INR 2-3)
Number of subjects: 28
Study 15451902 — intervention group
Group type: EXPERIMENTAL
Intervention: AS‐3201 at 5 mg/day
Number of subjects: 0
Study 15451902 — intervention group
Group type: EXPERIMENTAL
Intervention: AS‐3201 at 20 mg/day
Number of subjects: 0
Study 15451902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11408332 — intervention group
Group type: COMPARATOR
Intervention: Dyslexic subjects
Number of subjects: 0
Study 9414368 — intervention group
Group type: EXPERIMENTAL
Intervention: Garments with different fastener types and locations
Number of subjects: 10
Study 7997846 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately salt restricted diet
Number of subjects: 34
Study 3073270 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon, type alpha (IFN) ointment, 7,000 Ul/gm
Number of subjects: 66
Study 3073270 — intervention group
Group type: COMPARATOR
Intervention: Carbowax 4,000 (placebo)
Number of subjects: 66
Study 31667901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanotextile (customized nanotextile)
Number of subjects: 53
Study 31667901 — intervention group
Group type: COMPARATOR
Intervention: Viscose (Tubifast™)
Number of subjects: 53
Study 30506302 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 28601108 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention with 5 group meetings, 9 personal motivational calls, 9 automated motivational calls
Number of subjects: 288
Study 28578180 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of social interactions with friends
Number of subjects: 178
Study 28578180 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived satisfaction with relationships
Number of subjects: 178
Study 28578180 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of family interaction
Number of subjects: 178
Study 23794185 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine fossa puncture (CFP)
Number of subjects: 29
Study 23794185 — intervention group
Group type: COMPARATOR
Intervention: Maxillary sinus clearance through middle meatal antrostomy (MMA)
Number of subjects: 29
Study 21849912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint-Interval Training (SIT) program: 6 35-m sprints at maximum effort with a 10-second recovery, performed in 2 sessions per week for 4 weeks
Number of subjects: 15
Study 21849912 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional training without SIT)
Number of subjects: 15
Study 19641928 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved Cutter Stapler (CCS)
Number of subjects: 60
Study 19641928 — intervention group
Group type: COMPARATOR
Intervention: Linear Stapler
Number of subjects: 60
Study 19641928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CCS and Linear Stapler
Number of subjects: 60
Study 17118480 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide treatment for 8 weeks
Number of subjects: 115
Study 15001324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of etanercept 25 mg (subcutaneously twice a week) and oral methotrexate (up to 20 mg every week)
Number of subjects: 682
Study 15001324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of etanercept and methotrexate
Number of subjects: 682
Study 15001324 — intervention group
Group type: COMPARATOR
Intervention: Etanercept alone
Number of subjects: 682
Study 15001324 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 682
Study 11368288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amifostine 910 mg/m2
Number of subjects: 689
Study 11368288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amifostine 200 mg/m2
Number of subjects: 689
Study 11368288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amifostine 340 mg/m2
Number of subjects: 689
Study 11368288 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin 100 mg/m2 and cyclophosphamide 1000 mg/m2)
Number of subjects: 689
Study 11368288 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 689
Study 9040548 — intervention group
Group type: EXPERIMENTAL
Intervention: Large morning meals (AM)
Number of subjects: 10
Study 9040548 — intervention group
Group type: COMPARATOR
Intervention: Large evening meals (PM)
Number of subjects: 10
Study 9040548 — intervention group
Group type: COMPARATOR
Intervention: Large evening meals (PM) in period 1
Number of subjects: 10
Study 7934153 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide (4 puffs of 0.02 mg)
Number of subjects: 29
Study 7934153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular atropine (0.5 mg)
Number of subjects: 29
Study 7934153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 puffs)
Number of subjects: 29
Study 3351153 — intervention group
Group type: COMPARATOR
Intervention: Indecainide 50 mg three times daily
Number of subjects: 10
Study 3351153 — intervention group
Group type: COMPARATOR
Intervention: Indecainide 75 mg three times daily
Number of subjects: 10
Study 3351153 — intervention group
Group type: COMPARATOR
Intervention: Indecainide 100 mg three times daily
Number of subjects: 10
Study 3351153 — intervention group
Group type: COMPARATOR
Intervention: Indecainide
Number of subjects: 10
Study 28966223 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week lifestyle modifications (combination of aerobic exercise training and dietary modification)
Number of subjects: 20
Study 28966223 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week lifestyle modifications
Number of subjects: 20
Study 28489239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate solution
Number of subjects: 65
Study 28489239 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin ointment
Number of subjects: 65
Study 24165901 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 145
Study 24165901 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic (LA)
Number of subjects: 145
Study 24165901 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB and LA
Number of subjects: 145
Study 23245290 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 cisplatin once every 3 weeks (arm A)
Number of subjects: 55
Study 23245290 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/m2 cisplatin once per week (arm B)
Number of subjects: 55
Study 20824851 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion
Number of subjects: 126
Study 20824851 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 126
Study 17481748 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous assessment of B-type natriuretic peptide (BNP), cardiac troponin I (cTNI), and C-reactive protein (CRP)
Number of subjects: 305
Study 16885989 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable fortification (ADJ)
Number of subjects: 32
Study 16885989 — intervention group
Group type: COMPARATOR
Intervention: Standard fortification (STD)
Number of subjects: 32
Study 14664686 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized treatment
Number of subjects: 0
Study 14664686 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist as a random term
Number of subjects: 0
Study 14664686 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation studies
Number of subjects: 0
Study 10936467 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine at a dose of 2.510 mg/m²/day (divided into two equal doses) given in an intermittent schedule (2 weeks on/1 week off)
Number of subjects: 0
Study 9182140 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV infection
Number of subjects: 528
Study 9182140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid level
Number of subjects: 528
Study 12959305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol dry powder capsules (DPC) 0.2 mg, 0.4 mg
Number of subjects: 24
Study 12959305 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol metered dose inhaler (MDI) 0.2 mg, 0.4 mg
Number of subjects: 24
Study 12959305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative doses of fenoterol DPC (0.2, 0.6, 1.4, 3.0, 6.2 mg)
Number of subjects: 24
Study 12959305 — intervention group
Group type: COMPARATOR
Intervention: Cumulative doses of fenoterol MDI (0.2, 0.6, 1.4, 3.0, 6.2 mg)
Number of subjects: 24
Study 3320307 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (0.025 mg/kg intravenously for eight dosages over 12 weeks)
Number of subjects: 52
Study 3320307 — intervention group
Group type: COMPARATOR
Intervention: OKT3 monoclonal antibody (first 2 weeks after transplantation)
Number of subjects: 52
Study 29621985 — intervention group
Group type: EXPERIMENTAL
Intervention: ReNACE psychoeducational intervention
Number of subjects: 200
Study 29621985 — intervention group
Group type: COMPARATOR
Intervention: General educational programme
Number of subjects: 200
Study 26937948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous unfractionated heparin (5000-10000 units/day) until postoperative day 7 (POD7)
Number of subjects: 206
Study 26937948 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 206
Study 26937948 — intervention group
Group type: COMPARATOR
Intervention: Ablative surgery and neck dissection without heparin
Number of subjects: 206
Study 24747805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (0.30ppm) inhalation during 1 hour of exercise
Number of subjects: 30
Study 24378268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg/day for one month
Number of subjects: 95
Study 24378268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 21074020 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Patient Decision Aid (PtDA) containing information and values guidance
Number of subjects: 63
Study 21074020 — intervention group
Group type: COMPARATOR
Intervention: Abridged Patient Decision Aid (PtDA) containing information only
Number of subjects: 63
Study 18828077 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI) pit pattern classification
Number of subjects: 62
Study 18828077 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular pattern intensity (VPI)
Number of subjects: 62
Study 18828077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NBI pit pattern and VPI
Number of subjects: 62
Study 18828077 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI pit pattern
Number of subjects: 62
Study 17273672 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg/day)
Number of subjects: 22
Study 17273672 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (0.75 mg/kg/day)
Number of subjects: 22
Study 14600548 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 0
Study 11339008 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic alcohol use (abstainers for 2-6 years)
Number of subjects: 17
Study 11339008 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 17
Study 8637698 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral-dose azithromycin (20 mg/kg)
Number of subjects: 64
Study 8637698 — intervention group
Group type: COMPARATOR
Intervention: Topical tetracycline eye ointment for 6 weeks
Number of subjects: 64
Study 1458621 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate swabs
Number of subjects: 0
Study 1458621 — intervention group
Group type: COMPARATOR
Intervention: Gauze swabs
Number of subjects: 0
Study 4025792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia with 12-15 ml 0.25% plain bupivacaine and general anesthesia (flunitrazepam 1.5-2 mg, pancuronium bromide 0.1 mg/kg)
Number of subjects: 50
Study 4025792 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanaesthesia (droperidol 0.1-0.2 mg/kg, fentanyl 0.01 mg/kg, pancuronium bromide 0.1 mg/kg, thiopentone 100-150 mg)
Number of subjects: 50
Study 31905097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine high-velocity, low-amplitude thrust (HVLAT)
Number of subjects: 50
Study 31905097 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 50
Study 29461363 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mm Hg capsule pressure
Number of subjects: 30
Study 29461363 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mm Hg capsule pressure
Number of subjects: 30
Study 29461363 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mm Hg capsule pressure
Number of subjects: 30
Study 29461363 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mm Hg capsule pressure
Number of subjects: 30